BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, Shu Y, Chang L, Jiang H, Gu Y. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. Oncologist 2019;24:883-e407. [PMID: 30877190 DOI: 10.1634/theoncologist.2019-0164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Li N, Deng W, Zhang G, Du Y, Guo Y, Ma Y, Wei C, Bie L, Zhang C, Song T, Luo S, Fang B. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. Front Oncol 2021;11:728854. [PMID: 34540697 DOI: 10.3389/fonc.2021.728854] [Reference Citation Analysis]
2 Reece M, Saluja H, Hollington P, Karapetis CS, Vatandoust S, Young GP, Symonds EL. The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. Front Genet 2019;10:1118. [PMID: 31824558 DOI: 10.3389/fgene.2019.01118] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
3 Cai X, Wei B, Li L, Chen X, Yang J, Li X, Jiang X, Lv M, Li M, Lin Y, Xu Q, Guo W, Gu Y. Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling. Onco Targets Ther 2020;13:11031-44. [PMID: 33154652 DOI: 10.2147/OTT.S266549] [Reference Citation Analysis]
4 Yan Z, Gu YY, Hu XD, Zhao Q, Kang HL, Wang M, Duan W, Guan Y. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncol Lett 2020;20:3035-45. [PMID: 32782621 DOI: 10.3892/ol.2020.11857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Song ZZ, Zhao LF, Zuo J, Fan ZS, Wang L, Wang YD. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism. Onco Targets Ther 2020;13:603-13. [PMID: 32021302 DOI: 10.2147/OTT.S222985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
6 Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;11:7787-7803. [PMID: 31496821 DOI: 10.2147/cmar.s215533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
8 Cao W, Li Y, Sun H, Yang C, Zhu J, Xie C, Li X, Wu J, Geng S, Wang L, Sun L, Geng G, Han H, Zhong C. Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway. Front Cell Dev Biol 2021;9:679806. [PMID: 34350176 DOI: 10.3389/fcell.2021.679806] [Reference Citation Analysis]
9 Petrelli F, Perego G, Ghidini A, Ghidini M, Borgonovo K, Scolari C, Nozza R, Rampulla V, Costanzo A, Varricchio A, Rausa E, Pietrantonio F, Zaniboni A. A systematic review of salvage therapies in refractory metastatic colorectal cancer. Int J Colorectal Dis 2020;35:783-94. [DOI: 10.1007/s00384-020-03571-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tian Z, Niu X, Yao W. Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. Front Oncol 2021;11:749083. [PMID: 34676173 DOI: 10.3389/fonc.2021.749083] [Reference Citation Analysis]
11 Mao J, Yang X, Lin J, Yang X, Wang D, Zhang L, Bai Y, Bian J, Long J, Xie F, Huang H, Sang X, Chen S, Zhao H. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. J Cancer 2021;12:1555-62. [PMID: 33532001 DOI: 10.7150/jca.53482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Dai C, Gong Q, Cheng Y, Su G. Regulatory mechanisms of Robo4 and their effects on angiogenesis. Biosci Rep 2019;39:BSR20190513. [PMID: 31160487 DOI: 10.1042/BSR20190513] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
13 Li HS, Yang LL, Zhang MY, Cheng K, Chen Y, Liu JY. Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review. Front Oncol 2020;10:548867. [PMID: 33194604 DOI: 10.3389/fonc.2020.548867] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Bai M, Li ZG, Ba Y. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment. Int J Gen Med 2021;14:1041-55. [PMID: 33790633 DOI: 10.2147/IJGM.S300968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Liu Z, Shan J, Yu Q, Wang X, Song X, Wang F, Li C, Yu Z, Yu J. Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment. Front Oncol 2021;11:643654. [PMID: 34178630 DOI: 10.3389/fonc.2021.643654] [Reference Citation Analysis]
16 Zhu A, Yuan P, Hu N, Li M, Wang W, Wang X, Yue J, Wang J, Luo Y, Ma F, Zhang P, Li Q, Xu B, Cao S, Lippi G, Naito Y, Osman MA, Marta GN, Franceschini G, Orlandi A. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. Cancer Biol Med 2021:j. [PMID: 34037346 DOI: 10.20892/j.issn.2095-3941.2020.0418] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Wang Z, Huang Y, Long L, Zhou L, Huang Y, Gan L, Pu A, Li S, Xie R. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression. J Ovarian Res 2021;14:91. [PMID: 34247630 DOI: 10.1186/s13048-021-00843-8] [Reference Citation Analysis]
18 Liu JY, Zhu BR, Wang YD, Sun X. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. Int J Clin Oncol 2020;25:1195-205. [PMID: 32215805 DOI: 10.1007/s10147-020-01644-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Wei B, Wang Y, Wang J, Cai X, Xu L, Wu J, Wang Y, Liu W, Gu Y, Guo W, Xu Q. Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway. Cancer Cell Int 2020;20:198. [PMID: 32514243 DOI: 10.1186/s12935-020-01290-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
20 Rong X, Liu H, Yu H, Zhao J, Wang J, Wang Y. Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs 2022. [PMID: 34997351 DOI: 10.1007/s10637-021-01205-3] [Reference Citation Analysis]
21 Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules 2021;26:7463. [DOI: 10.3390/molecules26247463] [Reference Citation Analysis]
22 Chen J, Wang J, Zou Y. Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report. Medicine (Baltimore) 2021;100:e24390. [PMID: 33663051 DOI: 10.1097/MD.0000000000024390] [Reference Citation Analysis]
23 Ding Y, Wang J, Zhu N, Xu D, Ding K, Yuan Y. Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review. Cancer Biol Ther 2020;21:1105-8. [PMID: 33151122 DOI: 10.1080/15384047.2020.1836549] [Reference Citation Analysis]
24 Huang L, Zhang X, Bai Y, Chua KLM, Xie Y, Shu X, Long B, Fan C, Lim DWT, Tan SH, Wee JTS, Wang Y, Wu Y, Chua MLK. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. Oral Oncol 2021;115:105222. [PMID: 33610004 DOI: 10.1016/j.oraloncology.2021.105222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]